Allergy Therapeutics plc (FRA:HHU)

Market Cap	384.04M -14.8%
Revenue (ttm)	65.68M +2.9%
Net Income	-55.22M
EPS	-0.01
Shares Out	n/a
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	n/a
Open	0.0520
Previous Close	0.0520
Day's Range	0.0520 - 0.0520
52-Week Range	0.0465 - 0.1320
Beta	n/a
Analysts	n/a
Price Target	n/a
Earnings Date	Dec 11, 2026

About Allergy Therapeutics

Allergy Therapeutics plc, a commercial biotechnology company, focuses on the diagnosis and treatment of allergic disorders in Germany, Austria, United Kingdom, Netherlands, Switzerland, Italy, Spain, and internationally. The company sells injectable and sublingual allergen-specific immunotherapies, and offers treatment of pollen-related allergies, particularly to grasses, weeds, and trees, as well as diagnostics products. Its products include Pollinex Quattro, Oralvac, Venomil, Venom ATL Polistes Dominula, Synbiotics, and Acarovac Plus. It also...

• Industry: Biological Products, Except Diagnostic Substances
• Founded: 1998
• Employees: 584
• Stock Exchange: Frankfurt Stock Exchange
• Ticker Symbol: HHU

Financial Performance

In fiscal year 2025, Allergy Therapeutics's revenue was 55.04 million, a decrease of -0.28% compared to the previous year's 55.20 million. Losses were -40.13 million, 3.91% more than in 2024.

Financial numbers in GBP

Data Source: S&P Global Market Intelligence

Fundamental and historical data is provided by S&P Global Market Intelligence.

Last checked:

Sep 18, 2026

Data Sources Report a data error